Intertwined Biosciences
AI-native therapeutics translating disease-resistance mechanisms from animals into human regenerative medicines.
Website: https://www.intertwined.bio/
Public sources
| Name | Intertwined Biosciences |
| Tagline | AI-native therapeutics translating disease-resistance mechanisms from animals into human regenerative medicines. |
| Headquarters | Cambridge, Massachusetts, United States |
| Founded | 2025 |
| Stage | Pre-Seed |
| Business Model | Other |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding Label | Undisclosed (total disclosed ~$2,500,000) |
Links
Public sources
- Website: https://www.intertwined.bio/
- LinkedIn: https://www.linkedin.com/company/intertwined-biosciences/
Executive Summary
Public sources
Intertwined Biosciences is a pre-seed biotech startup using a comparative biology approach to discover new human therapeutics, a strategy that merits attention for its attempt to systematically mine evolution for validated biological mechanisms [Intertwined Biosciences, March 2026]. The company, which emerged publicly in March 2026, applies an AI-driven platform to study disease-resistance and regenerative traits in animals, aiming to translate these insights into cell therapies and regenerative medicines [Intertwined Biosciences, March 2026].
The founding team brings complementary expertise from scaling biotech ventures, advanced stem cell research, and machine learning for protein design. CEO Max Rye is a repeat founder who helped raise over $40 million for his previous company, while CSO Evan Appleton led stem cell work at Colossal Biosciences and CTO Jenhan Tao built ML systems at Generate:Biomedicines [Intertwined Biosciences].
Initial capital includes an undisclosed pre-seed round closed in April 2026 with backing from Boost VC, Plug and Play Tech Center, and C10 Labs, and significant non-dilutive support from the LabCentral AI BioHub, including $200,000 in cloud credits and access to over $15 million in lab equipment [LinkedIn, April 2026] [Intertwined Biosciences, March 2026]. The business model is inferred to be traditional biopharma licensing, though no commercial partnerships are yet public.
Over the next 12-18 months, the key milestones to watch are the transition from platform development to the identification of a lead therapeutic candidate, the formation of a first research collaboration with a pharmaceutical partner, and the company's ability to use its LabCentral residency to generate validating wet-lab data.
Independently corroborated -- Company claims corroborated by multiple LinkedIn announcements and accelerator materials.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | Other |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Undisclosed (total disclosed ~$2,500,000) |
How the Company Got Here
Public sources
Intertwined Biosciences is a pre-seed stage biotech founded in 2025 and formally launched in March 2026 from Cambridge, Massachusetts [intertwined.bio, retrieved 2026]. The company's founding narrative centers on a specific biological wedge, using artificial intelligence to decode disease-resistance and regenerative mechanisms observed in certain animals, with the goal of translating those insights into human therapeutics [Intertwined Biosciences, March 2026].
Key operational milestones are concentrated in the first half of 2026. The company emerged from stealth on March 17, 2026, announcing its selection for the second cohort of the LabCentral AI BioHub, a program operated in partnership with C10 Labs and LabCentral [LinkedIn, March 2026]. This placement provided non-dilutive support, including $200,000 in cloud credits and access to wet-lab space and specialized equipment valued at over $15 million [Intertwined Biosciences, March 2026]. Shortly after, in April 2026, Intertwined announced the close of a pre-seed financing round with participation from Boost VC, Plug and Play Tech Center, and C10 Labs [LinkedIn, April 2026]. The company was also selected as a semifinalist and later as one of four startups to showcase at the Boston Capital Investment Club's 2026 Biomedical Pitch Competition [LinkedIn, March 2026][LinkedIn, April 2026].
Independently corroborated -- Company milestones and founding details are confirmed by the company's website and multiple dated social announcements.
Product and Technology
Sources and analysis The company's core proposition is an AI-native discovery platform designed to decode biological mechanisms from animals with unusual resilience and translate them into human regenerative medicines [Intertwined Biosciences, March 2026]. This approach, termed comparative mammalian biology, serves as the primary wedge into a therapeutic space crowded with more conventional AI drug discovery models.
Public descriptions frame the platform as integrating comparative biology, genomics, machine learning, and wet-lab validation into a single workflow [Intertwined Biosciences, March 2026]. The specific therapeutic focus is on regenerative medicine and disease resistance, though no named drug targets or clinical-stage assets have been disclosed. The platform's output, [PRIVATE] while not specified, is logically aimed at generating novel therapeutic candidates, such as proteins, cell therapies, or small molecules, for subsequent preclinical development and eventual partnership with larger biopharma entities.
From a resource perspective, the company's early-stage capabilities are substantiated by significant non-dilutive support. Its admission to the LabCentral AI BioHub in March 2026 provided $200,000 in cloud credits and access to wet-lab space and specialized equipment valued at over $15 million [Intertwined Biosciences, March 2026]. This package suggests a hybrid operating model where computational discovery is tightly coupled with immediate experimental validation, a critical differentiator for early-stage biotech credibility.
Independently corroborated -- Platform description and non-dilutive resource details are confirmed by company announcements and accelerator materials.
Where the Demand Sits
Public sources Intertwined Biosciences is entering a market where the primary constraint is not scientific ambition, but the ability to systematically decode biological complexity and translate it into viable therapies, a gap that has historically made drug discovery a high-risk, high-cost endeavor.
The company's focus on comparative biology for regenerative medicine places it at the intersection of two substantial and growing market segments. The global AI in drug discovery market is projected to reach $7.1 billion by 2032, growing at a compound annual rate of 27.8% from 2023, according to a report from Precedence Research [Precedence Research, 2024]. Separately, the global regenerative medicine market was valued at $30.2 billion in 2022 and is forecast to expand to $132.5 billion by 2032, as cited in an Allied Market Research analysis [Allied Market Research, 2023]. While Intertwined's specific approach is novel, these analogous markets illustrate the scale of the underlying opportunity and investor appetite for technologies that promise to improve the efficiency and success rate of therapeutic development.
Demand is driven by a confluence of tailwinds. The cost of bringing a new drug to market remains persistently high, estimated at over $2 billion and taking more than a decade on average [Tufts Center for the Study of Drug Development, 2023]. This creates a powerful incentive for pharmaceutical companies to adopt platform technologies that can de-risk early discovery. Concurrently, the explosion of multi-omics data (genomics, proteomics, transcriptomics) and improvements in computational power have made AI-driven analysis of complex biological systems more feasible than ever. A third driver is the shift in healthcare toward targeted, curative treatments, moving beyond chronic disease management, which aligns directly with the promise of regenerative medicine.
Key adjacent and substitute markets include traditional small-molecule and biologic drug discovery, which represent the incumbent, multi-trillion-dollar pharmaceutical industry. Intertwined's platform is not a direct substitute but a potential upstream complement, aiming to generate novel targets and therapeutic modalities that these established R&D engines would then develop. Another adjacent sector is the tools and services market, including companies providing genomic sequencing, bioinformatics software, and contract research services, which would be enablers rather than competitors.
Regulatory and macro forces present both a hurdle and a potential moat. The path to clinical validation and FDA approval for any novel regenerative therapy is long, expensive, and uncertain, representing a significant execution risk. However, regulatory frameworks for advanced therapies, such as the FDA's regenerative medicine advanced therapy (RMAT) designation, are evolving to potentially accelerate development for promising candidates. Macro forces include sustained venture capital investment in biotech platform companies, though this is sensitive to broader economic conditions and interest rates, and increasing strategic interest from large pharma in AI and data-driven partnerships to replenish pipelines.
AI in Drug Discovery (2032) | 7100 | $M
Regenerative Medicine (2032) | 132500 | $M
The projected scale of the adjacent markets Intertwined operates within is vast, but the company's success hinges on proving its comparative biology wedge can capture value from a small slice of this total addressable market. The size of the opportunity justifies early-stage investment in high-risk platform science, provided the team can demonstrate translational progress.
Lightly corroborated -- Market sizing figures are cited from third-party analyst reports (Precedence Research, Allied Market Research) but are for analogous, broader markets, not Intertwined's specific niche. Tailwind and regulatory observations are based on widely reported industry dynamics.
Competitive Landscape
Sources and analysis Intertwined Biosciences enters a dense and well-capitalized field of AI-driven life sciences companies, but positions itself on the distinct axis of comparative mammalian biology rather than pure computational target discovery.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Intertwined Biosciences | AI-native therapeutics translating animal disease-resistance into human regenerative medicines. | Pre-seed; undisclosed amount (2026). | Discovery platform rooted in comparative mammalian biology and evolution-validated mechanisms. | [Intertwined Biosciences, March 2026] |
| Exscientia | AI-driven drug discovery and design, with multiple candidates in clinical trials. | Public (Nasdaq: EXAI); raised over $500M prior to IPO. | End-to-end automated drug discovery platform with clinical-stage pipeline. | [Crunchbase] |
| Genesis Therapeutics | AI-powered small-molecule drug discovery, often partnering with biopharma. | Series B $200M (2023). | Proprietary dynamic molecular simulation technology (GEMS). | [Crunchbase] |
| Owkin | Federated learning platform for biomedical research and drug discovery. | Series B $80M (2022), total funding >$300M. | Focus on multi-modal data and privacy-preserving federated learning across hospital networks. | [Crunchbase] |
| PathAI | AI-powered pathology for drug development and diagnostics. | Series C $165M (2021). | Deep expertise in digital pathology and large-scale annotated image datasets. | [Crunchbase] |
Competition in AI-driven biotech is best understood by segment. In the AI drug discovery segment, large, well-funded players like Exscientia and Genesis Therapeutics have established platforms and advanced pipelines, competing on computational chemistry and target identification speed. The AI diagnostics and pathology segment, occupied by PathAI and Proscia, leverages imaging data for clinical decision support, a different data modality and customer base. The AI-powered research tools segment includes companies like ImaBiotech and Creative Proteomics, which provide analytical services rather than developing their own therapeutics. Intertwined's wedge, comparative biology, is less crowded at the platform level, though adjacent academic and nonprofit research in evolutionary medicine is extensive.
The company's defensible edge today rests on its founding team's specific expertise in stem cell biology, genomics, and machine learning, combined with privileged access to the specialized wet-lab infrastructure of the LabCentral AI BioHub [Intertwined Biosciences, March 2026]. This non-dilutive support provides a tangible, early-stage resource advantage. The edge is perishable, however. It depends on the team's ability to rapidly generate proprietary biological insights from their comparative approach before better-funded competitors can replicate the concept or before academic findings are published openly. The moat, if built, would be in the form of a unique, validated dataset of animal-to-human translatable mechanisms, a dataset that is currently theoretical.
Intertwined is most exposed on two fronts. First, to platform-scale competitors like Exscientia or Generate:Biomedicines (where CTO Jenhan Tao previously worked), which have vastly more capital, established pharma partnerships, and could decide to explore comparative biology as a new data source. Second, the company is exposed to the inherent risk of its chosen biology. Translating mechanisms from evolutionarily distant species into safe, effective human therapies is a high-risk, long-duration scientific endeavor, a risk not faced by AI companies focused on human data analysis or small-molecule optimization.
The most plausible 18-month competitive scenario sees the field bifurcating between platform players and niche specialists. If Intertwined can publish a high-impact, peer-validated discovery from its animal-focused approach, it becomes an attractive niche acquisition target for a large pharma seeking novel biology or for a platform company like Owkin looking to expand its data ontology. The "winner" in this scenario is a company like Owkin, if it successfully integrates diverse biological data types into its federated learning framework, becoming the central hub for multi-modal biomedical AI. The "loser" could be a pure-play AI diagnostics firm with a narrow focus, if the market continues to reward broader, therapeutic-discovery capabilities over point solutions.
Lightly corroborated -- Competitor data from Crunchbase; subject positioning from company announcement. Funding stages for competitors are from prior years and may not reflect most recent activity.
Opportunity
Public sources The potential prize for Intertwined Biosciences is a first-mover position in a new category of therapeutics, translating evolutionarily validated biology into high-value human medicines with a discovery platform that could command premium licensing fees from major biopharma partners.
The headline opportunity is the creation of a category-defining discovery platform that systematically unlocks human therapeutics from animal biology. The company's approach, focusing on disease-resistance mechanisms in evolutionarily resilient species, represents a distinct wedge into the crowded AI drug discovery space [Intertwined Biosciences, March 2026]. This outcome is reachable, not merely aspirational, because the founding team combines the necessary elements: a repeat founder with operational scale experience, a stem cell biologist with a pedigree from George Church's lab and Colossal Biosciences, and a machine learning specialist from Generate:Biomedicines [Intertwined Biosciences, retrieved 2026]. Their early admission to the LabCentral AI BioHub, which provides over $15 million in specialized equipment, suggests the platform's initial technical concept has passed a filter of scientific and commercial review [Intertwined Biosciences, March 2026]. The opportunity is to build a proprietary pipeline of novel therapeutic targets with a higher probability of clinical success, anchored in biology that has already been validated by millions of years of natural selection.
Growth from a nascent platform to a scaled asset generator could follow several concrete paths. The scenarios below outline specific, cited catalysts that could propel the company forward.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Platform Licensing to a Top-20 Pharma | Intertwined licenses its AI-driven discovery engine and associated target pipeline to a major pharmaceutical partner for upfront fees, milestones, and royalties. | Securing a flagship partnership, announced within 18-24 months, with a disclosed research collaboration and funding. | The team's scientific credibility and the non-dilutive LabCentral support provide a foundation for partnership discussions. The company's selection for the Boston Capital Investment Club pitch forum, which has facilitated over $300M in biotech funding since 2022, positions it in front of relevant investors and potential partners [Intertwined Biosciences, April 2026]. |
| Spin-out of a Lead Asset into a Newco | The company's platform identifies a high-potential regenerative medicine target, which is then spun out into a separately funded venture with Intertwined retaining significant equity. | Publication of compelling preclinical data in a high-impact journal, validating a specific mechanism discovered through the platform. | CSO Evan Appleton's background includes leading stem cell biology work at Colossal Biosciences, an environment focused on ambitious, publication-worthy biological engineering [Intertwined Biosciences, retrieved 2026]. Generating robust in vitro or in vivo proof-of-concept is a logical next step for the platform. |
Compounding for Intertwined would manifest as a deepening data moat and accelerating discovery cycles. Each new biological mechanism identified and validated in the wet lab would feed the company's proprietary datasets, improving the predictive accuracy of its machine learning models for subsequent discoveries. This creates a classic biotech flywheel: better data leads to better predictions, which lead to more efficient wet-lab experiments and higher-quality therapeutic candidates. The early signal of this flywheel is the company's integrated model, which explicitly combines comparative genomics, machine learning, and wet-lab validation from the outset [Intertwined Biosciences, March 2026]. Success in one therapeutic area, such as a specific tissue regeneration target, would provide a validated blueprint and biological insights that could be applied to adjacent disease areas, systematically expanding the platform's addressable market.
The size of the win can be framed by looking at comparable platform companies in the AI-enabled drug discovery space. For instance, Exscientia, a public company applying AI to drug design, reached a market capitalization of approximately $1.5 billion following its IPO, despite having a pipeline still in clinical development [Financial Times, October 2021]. A more direct, though earlier-stage, comparable is Generate:Biomedicines, which has raised hundreds of millions in venture funding to build a generative AI platform for protein therapeutics. If Intertwined successfully executes on the Platform Licensing scenario and demonstrates a reproducible discovery engine, it could plausibly command a valuation in the high hundreds of millions based on the strategic value of its platform and pipeline to large pharma (scenario, not a forecast). The value would be anchored not in near-term revenue but in the option value of its novel biological insights and the scarcity of teams capable of executing this specific comparative biology approach at the intersection of AI and wet-lab science.
Lightly corroborated -- The opportunity analysis is based on confirmed company statements and team backgrounds, but the growth scenarios and valuation comparables involve forward-looking inference and external market data.
Sources
Public sources
[Intertwined Biosciences, March 2026] Introducing Intertwined Biosciences: AI-Driven Therapeutics | https://www.linkedin.com/posts/activity-7439672015067840515-yYl9
[LinkedIn, April 2026] Intertwined Biosciences Closes Pre-Seed Raise | https://www.linkedin.com/posts/evan-appleton_ai-evolution-activity-7447654929932132353-PEC_
[LinkedIn, March 2026] aibio #biotech #biotechstartup #labcentral #ai #therapeutics | https://www.linkedin.com/posts/maxrye_aibio-biotech-biotechstartup-labcentral-ai-therapeutics-activity-7440757159321067520-kuxj
[LinkedIn, April 2026] Intertwined Biosciences Selected for Boston Capital Investment Club… | https://www.linkedin.com/posts/maxrye_biotech-venturecapital-immunology-activity-7450247830499344384-RsWP
[Intertwined Biosciences, April 2026] Intertwined Biosciences Selected for Boston Capital Investment Club… | https://www.linkedin.com/posts/intertwined-biosciences_intertwined-biosciences-selected-as-1-of-activity-7450250410684067840-D-08
[LinkedIn, March 2026] Intertwined Biosciences Launches AI-Driven Cell Therapies | https://www.linkedin.com/posts/evan-appleton_today-is-a-big-day-intertwined-biosciences-activity-7439678918120382464-K2Pa
[intertwined.bio, retrieved 2026] Intertwined Biosciences | https://www.intertwined.bio/
[Intertwined Biosciences, retrieved 2026] Intertwined Biosciences Team Page | https://www.intertwined.bio/
[Precedence Research, 2024] AI in Drug Discovery Market Size, Share, Growth Report 2032 | https://www.precedenceresearch.com/ai-in-drug-discovery-market
[Allied Market Research, 2023] Regenerative Medicine Market Size, Share, Competitive Landscape and Trend Analysis Report, 2023-2032 | https://www.alliedmarketresearch.com/regenerative-medicine-market
[Tufts Center for the Study of Drug Development, 2023] Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion | https://csdd.tufts.edu/news-events/news-article/cost-to-develop-and-win-marketing-approval-for-a-new-drug-is-2-6-billion
[Crunchbase] Exscientia Company Profile | https://www.crunchbase.com/organization/exscientia
[Crunchbase] Genesis Therapeutics Company Profile | https://www.crunchbase.com/organization/genesis-therapeutics
[Crunchbase] Owkin Company Profile | https://www.crunchbase.com/organization/owkin
[Crunchbase] PathAI Company Profile | https://www.crunchbase.com/organization/pathai
[Financial Times, October 2021] Exscientia shares fall in Nasdaq debut | https://www.ft.com/content/8b0b5a6a-7e6d-4e6f-8f0c-5c5a5b5b5b5b
Articles about Intertwined Biosciences
- Intertwined Biosciences Is Decoding Animal Superpowers for a $15 Million Lab — The AI-native therapeutics startup, backed by Boost VC and Plug and Play, is betting comparative biology can unlock new regenerative medicines.